Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD), placing ...

Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world. Nonetheless we did track some significant moves including a couple of CEO ...